Product and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2021

Sales of the Company’s products were as follows:


	Three Months Ended September 30,												Nine Months Ended September 30,
	2021						2020						2021						2020
($ in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Women’s Health
Nexplanon/Implanon NXT	$	120	$	55	$	175	$	137	$	52	$	189	$	389	$	154	$	543	$	374	$	142	$	515
Follistim AQ	29		32		61		20		31		50		81		97		178		60		75		135
NuvaRing	21		28		49		25		33		58		68		79		147		86		98		184
Ganirelix Acetate Injection	5		20		25		4		21		25		19		66		85		7		48		55
Cerazette	—		18		18		—		18		18		—		53		53		—		51		51
Other Women's Health (1)	18		35		53		45		39		84		80		111		191		121		103		224
Biosimilars
Renflexis	48		6		54		34		4		38		119		17		136		88		8		96
Ontruzant	9		47		56		—		37		37		20		81		101		1		77		78
Brenzys	—		14		14		—		23		23		—		35		35		—		52		52
Other Biosimilars (1)	—		16		16		—		1		1		—		34		34		—		1		1
Established Brands
Cardiovascular
Zetia	1		90		91		(1)		103		103		6		276		282		(4)		389		384
Vytorin	3		38		41		3		44		47		8		119		127		9		130		139
Atozet	—		114		114		—		111		111		—		347		347		—		348		348
Rosuzet	—		15		15		—		32		32		—		48		48		—		94		94
Cozaar/Hyzaar	3		84		87		5		86		91		9		256		265		17		274		291
Zocor	1		17		18		1		17		18		3		46		49		1		56		57
Other Cardiovascular (1)	—		31		31		—		37		37		—		99		99		—		124		124
Respiratory
Singulair	2		98		100		4		78		82		10		289		300		14		324		338
Nasonex	—		49		48		—		41		41		3		141		144		9		151		160
Dulera	48		8		56		51		8		59		121		25		146		155		26		181
Clarinex	2		27		28		2		23		25		5		78		83		5		104		109
Asmanex	14		2		15		20		1		21		43		5		48		58		5		64
Other Respiratory (1)	—		3		3		—		11		11		—		15		16		1		25		26
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		65		65		—		68		68		—		184		184		—		204		204
Fosamax	1		45		46		1		45		46		3		130		132		3		137		140
Diprospan	—		34		34		—		33		33		—		92		92		—		87		87
Diprosone	—		22		22		—		22		22		1		64		65		1		58		59
Other Non-Opioid Pain, Bone and Dermatology (1)	9		47		57		3		49		52		11		137		148		5		140		144
Other
Proscar	—		27		27		—		59		60		1		91		92		1		152		154
Propecia	1		33		34		2		30		32		5		96		101		7		83		91
Sinemet	—		17		17		—		18		18		—		54		54		(1)		58		58
Remeron	1		17		19		1		16		16		3		48		51		2		46		47
Other (1)	9		49		59		15		48		63		29		128		157		44		135		179
Other (2)	1		51		52		(1)		3		2		(2)		171		168		4		46		50
Total sales	$	346	$	1,254	$	1,600	$	371	$	1,242	$	1,613	$	1,035	$	3,666	$	4,701	$	1,068	$	3,851	$	4,919

U.S. plus international may not equal total due to rounding.

(1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.

(2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

Consolidated revenues by geographic area

Combined sales by geographic area where derived are as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2021		2020		2021		2020
Europe and Canada	$	410	$	426	$	1,314	$	1,286
United States	346		371		1,035		1,068
Asia Pacific and Japan	287		354		874		1,190
China	252		225		693		655
Latin America, Middle East, Russia and Africa	238		228		595		649
Other(1)	67		9		190		71
	$	1,600	$	1,613	$	4,701	$	4,919

(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.